Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis

Annals of Neurology

Volumn 73, Issue 5, 2013, Pages 626-636

  Chiurchiù, Valerio ^a,b   Cencioni, Maria Teresa ^b   Bisicchia, Elisa ^a,b   De Bardi, Marco ^b   Gasperini, Claudio ^c   Borsellino, Giovanna ^b   Centonze, Diego ^b,d   Battistini, Luca ^b   Maccarrone, Mauro ^b  

^a UNIVERSITY OF TERAMO   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANANDAMIDE; CYTOKINE; ENDOCANNABINOID; FATTY ACID AMIDASE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ADULT; AGED; ARTICLE; CELL FUNCTION; CELL STIMULATION; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MULTIPLE SCLEROSIS; MYELOID DENDRITIC CELL; NEUROMODULATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TH1 CELL; TH17 CELL;

ADOLESCENT; ADULT; AGED; AMIDOHYDROLASES; ARACHIDONIC ACIDS; CANNABINOID RECEPTOR AGONISTS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; ENDOCANNABINOIDS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELOID CELLS; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; YOUNG ADULT;

EID: 84878320781     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23875     Document Type: Article

References (32)

1. Gandhi R, Laroni A, Weiner HL,. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol 2010; 221: 7-14.
2. Zozulya AL, Clarkson BD, Ortler S, et al. The role of dendritic cells in CNS autoimmunity. J Mol Med (Berl) 2010; 88: 535-544.
3. MacDonald KP, Munster DJ, Clark GJ, et al. Characterization of human blood dendritic cell subsets. Blood 2002; 100: 4512-4520.
4. Schreibelt G, Tel J, Sliepen KH, et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 2010; 59: 1573-1582.
5. Shortman K, Heath WR,. Immunity or tolerance? That is the question for dendritic cells. Nat Immunol 2001; 2: 988-989.
6. Karni A, Abraham M, Monsonego A, et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006; 177: 4196-4202.
7. Stasiolek M, Bayas A, Kruse N, et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006; 129: 1293-1305.
8. Huang YM, Xiao BG, Ozenci V, et al. Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. J Neuroimmunol 1999; 99: 82-90.
9. Zhang H, Hilton DA, Hanemann CO, Zajicek J,. Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D-evidence for altered expression in multiple sclerosis. Brain Pathol 2011; 21: 544-557.
10. Rossi S, Bernardi G, Centonze D,. The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp Neurol 2010; 224: 92-102.
11. Correa FG, Mestre L, Docagne F, et al. The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. Vitamin Horm 2009; 81: 207-230.
12. Centonze D, Battistini L, Maccarrone M,. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Des 2008; 14: 2370-2342.
13. Baker D, Pryce G,. The endocannabinoid system and multiple sclerosis. Curr Pharm Des 2008; 14: 2326-2336.
14. Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P,. Endocannabinoids and immune regulation. Pharmacol Res 2009; 60: 85-92.
15. Centonze D, Bari M, Rossi S, et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 2007; 130: 2543-2553.
16. Cencioni MT, Chiurchiù V, Catanzaro G, et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 2010; 5:. e8688.
17. Correa F, Hernangõmez-Herrero M, Mestre L, et al. The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross- talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav Immun 2011; 25: 736-749.
18. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
19. Jensen SS, Gad M,. Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktails: targeting dendritic cells in autoimmunity. J Inflamm (Lond) 2010; 27: 7-37.
20. Pasquariello N, Catanzaro G, Marzano V, et al. Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis. J Biol Chem 2009; 284: 29413-29426.
21. Bayas A, Stasiolek M, Kruse N, et al. Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis. Clin Exp Immunol 2009; 157: 332-342.
22. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863-869.
23. Chen Y, Langrish CL, McKenzie B, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006; 116: 1317-1326.
24. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748.
25. McKenzie BS, Kastelein RA, Cua DJ,. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006; 27: 17-23.
26. Maldonado RA, von Andrian UH,. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 2010; 108: 111-165.
27. Venken K, Hellings N, Thewissen M, et al. Compromised CD4+CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 2008; 123: 79-89.
28. Swiecki M, Colonna M,. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 2010; 234: 142-162.
29. Piomelli D,. The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 2005; 6: 672-679.
30. Di Marzo V, Bisogno T, De Petrocellis L,. Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. Chem Biol 2007; 14: 741-756.
31. Kerr DM, Burke NN, Ford GK, et al. Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. Neuroscience 2012; 204: 53-63.
32. Clapper JR, Moreno-Sanz G, Russo R, et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosi 2010; 13: 1265-1270.